Skip to content
Medical Health Aged Care

All Health Professions Must Support Primary Care Reforms

Australian College of Nursing 2 mins read

The Australian College of Nursing (ACN) is calling on all health professions to work collaboratively to support and promote the much-needed primary health care reforms that will flow from the Unleashing the Potential of our Health Workforce – Scope of Practice Review, which is expected to deliver its final report in October this year.


In its response to the Review’s Issues Paper 2, ACN stresses that alignment of professional bodies in supporting reforms is crucial for challenging existing norms within current models of care.


ACN CEO, Emeritus Professor Leanne Boyd FACN, said that unified leadership and support are essential to ensuring all disciplines comprehend the impact of reforms on their scope of practice.


“All the professions and the professional bodies must be united in putting patients first,” Professor Boyd said.


“The reform priority is equitable access to affordable, high-quality, and safe primary health care for all Australians, no matter where they live.


“By fostering collaboration and shared commitment among professional bodies, the implementation of transformative changes can be more effectively navigated and implemented.


“ACN strongly believes that the Review outcomes will not fragment care, as claimed by some advocates. Instead, they will provide a framework for a more collaborative patient-focussed approach to care.


“This will lead to improved health outcomes and more efficient and equitable healthcare delivery across the nation.”


Professor Boyd said that a collaborative, respectful approach to care will improve health outcomes and provide patients with a better experience along their healthcare journeys.


“Recognising and acknowledging the overlap of capabilities is necessary when providing health care,” Professor Boyd said.


“It ensures that all healthcare practitioners know what each can do under what circumstances and to accept that, within a multidisciplinary team, some tasks and functions will be shared to enable better, safer, and more timely care for the patient.


“Legislation must be reviewed and amended to remove funding barriers to more effective multi-disciplinary primary health care.


“Amendments to the Health Insurance Act would enable many healthcare professionals within primary health care to be remunerated for the time and activities they are already undertaking.


“ACN will strongly support reforms to funding and payment models that incentivise multidisciplinary care teams to work to full scope of practice,” Professor Boyd said.


The ACN Response to Scope of Practice Review – Issues Paper 2 is at


For more information:

John Flannery 0419 494 761




Social media channels:           Facebook:
                                                     X (Twitter):


More from this category

  • Medical Health Aged Care
  • 24/06/2024
  • 17:07
Takeda Pharmaceutical Company Limited

Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies

LIVTENCITY Is the First and Only Post-Transplant Anti-CMV Treatment Approved in Japan That Targets/Inhibits UL97 Protein Kinase1 CMV Is One of the Most Common…

  • Contains:
  • CharitiesAidWelfare, Medical Health Aged Care
  • 24/06/2024
  • 16:20
National Rural Health Alliance

Community-led innovation to revolutionise healthcare access in rural Australia

The National Rural Health Alliance (the Alliance) is delighted that the Minister for Health and Aged Care, the Hon Mark Butler, has today announced…

  • Contains:
  • Business Company News, Medical Health Aged Care
  • 24/06/2024
  • 12:25
Jane Morgan Management

Imugene (ASX:IMU) Doses First Patient in Pioneering Phase 1 onCARlytics Trial

Sydney, Australia, 24 June 2024: Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company, is thrilled to announce the dosing of the first patient in the intravenous (IV) infusion combination arm of its Phase 1 onCARlytics (CF33-CD19) clinical trial. This groundbreaking trial, named OASIS, is being conducted at City of Hope in California and is designed to transform the treatment landscape for patients with advanced solid tumors. The OASIS trial is a world-first, combining a CD19-expressing oncolytic virus with a CD19-targeting drug. The trial aims to recruit 40-45 patients with advanced solid cancers that have metastasized, with preliminary early combination data…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.